These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2385958)

  • 21. Development of a novel subunit vaccine that protects cotton rats against both human respiratory syncytial virus and human parainfluenza virus type 3.
    Homa FL; Brideau RJ; Lehman DJ; Thomsen DR; Olmsted RA; Wathen MW
    J Gen Virol; 1993 Sep; 74 ( Pt 9)():1995-9. PubMed ID: 8397289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of passive antibody on the immune response of cotton rats to purified F and G glycoproteins of respiratory syncytial virus (RSV).
    Murphy BR; Prince GA; Collins PL; Hildreth SW; Paradiso PR
    Vaccine; 1991 Mar; 9(3):185-9. PubMed ID: 2042390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection.
    Hancock GE; Speelman DJ; Frenchick PJ; Mineo-Kuhn MM; Baggs RB; Hahn DJ
    Vaccine; 1995 Mar; 13(4):391-400. PubMed ID: 7793137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune response to experimentally induced infection with respiratory syncytial virus: possible role in the development of pulmonary disease.
    Piedra PA; Camussi G; Ogra PL
    J Gen Virol; 1989 Feb; 70 ( Pt 2)():325-33. PubMed ID: 2732693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liposome encapsulation of a soluble recombinant fragment of the respiratory syncytial virus (RSV) G protein enhances immune protection and reduces lung eosinophilia associated with virus challenge.
    Mader D; Huang Y; Wang C; Fraser R; Issekutz AC; Stadnyk AW; Anderson R
    Vaccine; 2000 Jan; 18(11-12):1110-7. PubMed ID: 10590333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice.
    Boelen A; Andeweg A; Kwakkel J; Lokhorst W; Bestebroer T; Dormans J; Kimman T
    Vaccine; 2000 Nov; 19(7-8):982-91. PubMed ID: 11115725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses.
    Murphy BR; Olmsted RA; Collins PL; Chanock RM; Prince GA
    J Virol; 1988 Oct; 62(10):3907-10. PubMed ID: 3047432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease.
    Hwang HS; Lee YT; Kim KH; Park S; Kwon YM; Lee Y; Ko EJ; Jung YJ; Lee JS; Kim YJ; Lee YN; Kim MC; Cho M; Kang SM
    Virology; 2016 Jul; 494():215-24. PubMed ID: 27123586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
    Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived.
    Connors M; Collins PL; Firestone CY; Murphy BR
    J Virol; 1991 Mar; 65(3):1634-7. PubMed ID: 1995956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of lung histopathology and bronchoalveolar lavage cytology in mice and cotton rats infected with respiratory syncytial virus.
    Vaux-Peretz F; Meignier B
    Vaccine; 1990 Dec; 8(6):543-8. PubMed ID: 2087875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
    Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
    Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The envelope proteins from purified respiratory syncytial virus protect mice from intranasal virus challenge.
    Levine S; Dillman TR; Montgomery PC
    Proc Soc Exp Biol Med; 1989 Apr; 190(4):349-56. PubMed ID: 2928348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge.
    Johnson TR; Parker RA; Johnson JE; Graham BS
    J Immunol; 2003 Feb; 170(4):2037-45. PubMed ID: 12574374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV.
    Waris ME; Tsou C; Erdman DD; Day DB; Anderson LJ
    J Virol; 1997 Sep; 71(9):6935-9. PubMed ID: 9261421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children.
    Belshe RB; Anderson EL; Walsh EE
    J Infect Dis; 1993 Oct; 168(4):1024-9. PubMed ID: 8376814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination with a heterologous respiratory syncytial virus chimeric FG glycoprotein demonstrates significant subgroup cross-reactivity.
    Oien NL; Brideau RJ; Thomsen DR; Homa FL; Wathen MW
    Vaccine; 1993; 11(10):1040-8. PubMed ID: 8212825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunization of cotton rats with the human respiratory syncytial virus F glycoprotein produced using a baculovirus vector.
    Wathen MW; Brideau RJ; Thomsen DR
    J Infect Dis; 1989 Feb; 159(2):255-64. PubMed ID: 2644369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bovine respiratory syncytial virus protects cotton rats against human respiratory syncytial virus infection.
    Piazza FM; Johnson SA; Darnell ME; Porter DD; Hemming VG; Prince GA
    J Virol; 1993 Mar; 67(3):1503-10. PubMed ID: 8437227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses.
    Murphy BR; Prince GA; Collins PL; Van Wyke Coelingh K; Olmsted RA; Spriggs MK; Parrott RH; Kim HW; Brandt CD; Chanock RM
    Virus Res; 1988 Aug; 11(1):1-15. PubMed ID: 2845680
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.